Stratum Biosciences, a New York City–based biotech company focused on combining AI with dermatology research, has raised $2 million in a seed funding round.
The round also saw the backers, including the Harvard Business School Alumni Angels of Greater New York and Skin Angels.
The company plans to use the funds to expand its AI-powered skin biology platform, analyzing over 200,000 skin samples to discover new insights and speed up product development. It will also build partnerships to turn these discoveries into new ingredients and formulation technologies.
A key part of Stratum’s growth is its participation in NVIDIA’s Inception program, which supports startups using advanced technology to transform industries. By using NVIDIA’s computing power Stratum aims to quickly analyze its skin biopsy database to discover new biomarkers, and insights that traditional research methods may have missed.
Stratum’s SkinSync™ platform has already revealed important new insights about how the skin is structured and functions, challenging long-standing beliefs about the skin barrier.
Over the past year, Stratum Biosciences has proven its approach by working with global consumer product companies to develop new active ingredients and formulations using its AI-powered SkinSync™ platform. These products focus on key skincare needs like hyperpigmentation and skin aging.
The company is quickly building more partnerships to turn skin biology research into new ingredients and technologies. Stratum is currently based at Johnson & Johnson’s JLABS@NYC accelerator in SoHo, New York.
Read More:VITL Raises $7.5M in Series A Funding
“As a dermatologist, I see that the biggest challenge in skin innovation is our limited understanding of skin biology,” said Dr. Ross Pearlman, CEO and Co-founder of Stratum Biosciences. “With modern AI, we can now uncover hidden mechanisms in the skin and turn them into new solutions for better skin health.”
“Our skin reflects what’s happening inside our bodies, and Stratum’s biobank holds valuable insights for new anti-aging solutions and more,” said Dr. Buu Duong, President and Co-founder. “We now have the tools to unlock these insights and create solutions at scale. Instead of just observing, we’re decoding the skin’s biology to change how the industry approaches longevity and health.”
“The scientific progress this team has made in a short time is impressive,” said Chief Scientific Officer Dr. David Osborne, former co-founder of Arcutis. “I’m excited to use my experience with Stratum’s platform to reshape our understanding of dermatology and improve skincare.”
About Stratum Biosciences
Founded in 2023 by Dr. Ross L. Pearlman and Dr. Buu T. Duong, Stratum Biosciences is a dermatology discovery company that uses a proprietary AI platform and over 200,000 real tissue samples to speed up the development of new ingredients and formulations for skincare and pharmaceutical products. Based at Johnson & Johnson’s JLABS incubator, the company works with global brands to solve major skin challenges, building a strong pipeline focused on areas like skin longevity, hyperpigmentation, and eczema.
Read More:Clasp Raises $20M Series B Funding
